18-fluorodeoxyglucose PET in people with active myelopathy Nov. 01, 2013 Overview إظهار النسخة النصية Overview Eoin P. Flanagan, M.B., B.Ch., an assistant professor of neurology and an Autoimmune Neurology fellow at Mayo Clinic in Rochester, Minnesota, discusses his article appearing in the November 2013 issue of Mayo Clinic Proceedings, which suggests that PET scans may give a clue to the underlying etiology in patients with spinal cord disease. VID-20432774 المتخصصون في المجالات الطبية 18-Fluorodeoxyglucose PET in Patients with Active Myelopathy